Q-omics provides the consensus-scored LPCAT2BP profile across patient tissues and cancer cell-line models. LPCAT2BP expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, LPCAT2BP is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, LPCAT2BP RNA expression shows 6,753 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, COAD, and STAD as cancer lineages where LPCAT2BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LPCAT2BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LPCAT2BP survival associations across molecular data types. LPCAT2BP RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LPCAT2BP RNA expression–survival associations across cancer types. High LPCAT2BP expression shows unfavorable associations in LIHC, DLBC, LUSC, LUAD and SKCM, but favorable associations in ESCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LIHC as the clearest survival context for LPCAT2BP RNA expression.
This table summarizes LPCAT2BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LPCAT2BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LPCAT2BP shows higher tumor expression in COAD, LUAD and BRCA. The COAD box plot shows higher LPCAT2BP RNA expression in tumor versus normal tissue (log2 FC = +0.017, t-test p = .013).
This table shows molecular features associated with LPCAT2BP in patient tissues and cancer cell lines. In patient samples, LPCAT2BP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
